IceCure Medical yesterday said it received Israeli AMAR authorization to use its freezing technology in specific indications.
The approval will allow the Israel-based company to use the technology to freeze benign and malignant tumors, including breast, lungs, bones, liver, lymphatic tissue, lymph nodes and endocrine glands.
“This specific approval in Israel is an important achievement that will support IceCure to expand our technology use. Doctors can now more easily destroy benign and malignant tumors for a wide range of indications that will help save and improve the lives of many patients,” CEO Eyal Shamir said in a press release. “The approval in Israel follows the recent approval of the American Medical Association applications for CPT Code Category 3 for ablating malignant breast tumors. We are confident these combined regulatory approvals will help further enhance clinical acceptance of our technology and advance our business development efforts to help make patient care more affordable and accessible worldwide.”
The cryoablation technology is a liquid nitrogen solution that destroys tumors safely, quickly and painlessly without the need for surgery. It is guided by CT or ultrasound and inserted into the tumor where the liquid nitrogen creates sub-zero temperatures, turning the tumors into ice balls, according to IceCure Medical. The freeze-thaw-freeze cycle destroys the targeted tissue and leaves healthy tissue undamaged. The debris from the procedure is absorbed by the body.
